Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 524

1.

Construction of a Novel Bispecific Antibody to Enhance Antitumor Activity against Lung Cancer.

Yin W, Zhu J, Gonzalez-Rivas D, Okumura M, Rocco G, Pass H, Jiang G, Yang Y.

Adv Mater. 2018 Oct 21:e1805437. doi: 10.1002/adma.201805437. [Epub ahead of print]

PMID:
30345557
2.

Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Carbone M, Amelio I, Affar EB, Brugarolas J, Cannon-Albright LA, Cantley LC, Cavenee WK, Chen Z, Croce CM, Andrea A, Gandara D, Giorgi C, Jia W, Lan Q, Mak TW, Manley JL, Mikoshiba K, Onuchic JN, Pass HI, Pinton P, Prives C, Rothman N, Sebti SM, Turkson J, Wu X, Yang H, Yu H, Melino G.

Cell Death Differ. 2018 Oct 15. doi: 10.1038/s41418-018-0213-5. [Epub ahead of print]

PMID:
30323273
3.

Integrative Molecular Characterization of Malignant Pleural Mesothelioma.

Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman DI, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti HS, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Salle F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, Research Network T, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson G, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M.

Cancer Discov. 2018 Oct 15. pii: CD-18-0804. doi: 10.1158/2159-8290.CD-18-0804. [Epub ahead of print]

PMID:
30322867
4.

Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation.

Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers M, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH Jr, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB 2nd, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM.

J Thorac Oncol. 2018 Sep 25. pii: S1556-0864(18)33121-6. doi: 10.1016/j.jtho.2018.08.2036. [Epub ahead of print]

PMID:
30266660
5.

PACIFIC: Time for a surgical IIIA uprising.

Pass HI.

J Thorac Cardiovasc Surg. 2018 Sep;156(3):1249-1254. doi: 10.1016/j.jtcvs.2018.05.059. Epub 2018 Jun 4. No abstract available.

PMID:
30017445
6.

Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.

Ooki A, Dinalankara W, Marchionni L, Tsay JJ, Goparaju C, Maleki Z, Rom WN, Pass HI, Hoque MO.

Oncogene. 2018 Jul 6. doi: 10.1038/s41388-018-0373-2. [Epub ahead of print]

PMID:
29980786
7.

Tissue and exosomal miRNA editing in Non-Small Cell Lung Cancer.

Nigita G, Distefano R, Veneziano D, Romano G, Rahman M, Wang K, Pass H, Croce CM, Acunzo M, Nana-Sinkam P.

Sci Rep. 2018 Jul 5;8(1):10222. doi: 10.1038/s41598-018-28528-1.

8.

Development and validation of response markers to predict survival and pleurodesis success in patients with malignant pleural effusion (PROMISE): a multicohort analysis.

Psallidas I, Kanellakis NI, Gerry S, Thézénas ML, Charles PD, Samsonova A, Schiller HB, Fischer R, Asciak R, Hallifax RJ, Mercer R, Dobson M, Dong T, Pavord ID, Collins GS, Kessler BM, Pass HI, Maskell N, Stathopoulos GT, Rahman NM.

Lancet Oncol. 2018 Jul;19(7):930-939. doi: 10.1016/S1470-2045(18)30294-8. Epub 2018 Jun 13.

PMID:
29908990
9.

Reply to D. de Fonseka et al.

Kindler HL, Rusch V, Bueno R, Ismaila N, Pass H, Sterman D, Hassan R.

J Clin Oncol. 2018 Sep 10;36(26):2746-2747. doi: 10.1200/JCO.2018.78.7333. Epub 2018 Jun 14. No abstract available.

PMID:
29902108
10.

Airway Microbiota Is Associated with Up-Regulation of the PI3K Pathway in Lung Cancer.

Tsay JJ, Wu BG, Badri MH, Clemente JC, Shen N, Meyn P, Li Y, Yie TA, Lhakhang T, Olsen E, Murthy V, Michaud G, Sulaiman I, Tsirigos A, Heguy A, Pass H, Weiden MD, Rom WN, Sterman DH, Bonneau R, Blaser MJ, Segal LN.

Am J Respir Crit Care Med. 2018 Jun 4. doi: 10.1164/rccm.201710-2118OC. [Epub ahead of print]

PMID:
29864375
11.

Stereotactic Body Radiation Therapy for Operable Early-Stage Lung Cancer: Findings From the NRG Oncology RTOG 0618 Trial.

Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, Schiff PB, Chang G, Loo BW Jr, Bradley JD, Choy H.

JAMA Oncol. 2018 Sep 1;4(9):1263-1266. doi: 10.1001/jamaoncol.2018.1251.

PMID:
29852037
12.

Sphenopalatine Ganglion Block to Treat Shoulder Tip Pain After Thoracic Surgery: Report of 2 Cases.

Grant GJ, Echevarria GC, Lax J, Pass HI, Oshinsky ML.

A A Pract. 2018 Aug 15;11(4):90-92. doi: 10.1213/XAA.0000000000000746.

PMID:
29634542
13.

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.

Barash U, Lapidot M, Zohar Y, Loomis C, Moreira A, Feld S, Goparaju C, Yang H, Hammond E, Zhang G, Li JP, Ilan N, Nagler A, Pass HI, Vlodavsky I.

J Natl Cancer Inst. 2018 Oct 1;110(10):1102-1114. doi: 10.1093/jnci/djy032.

PMID:
29579286
14.

Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.

PMID:
29524617
15.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

16.

Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.

Nicholson AG, Tsao MS, Travis WD, Patil DT, Galateau-Salle F, Marino M, Dacic S, Beasley MB, Butnor KJ, Yatabe Y, Pass HI, Rusch VW, Detterbeck FC, Asamura H, Rice TW, Rami-Porta R.

Arch Pathol Lab Med. 2018 May;142(5):645-661. doi: 10.5858/arpa.2017-0245-RA. Epub 2018 Feb 26.

PMID:
29480761
17.

Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Thompson JK, Shukla A, Leggett AL, Munson PB, Miller JM, MacPherson MB, Beuschel SL, Pass HI, Shukla A.

Oncotarget. 2017 Dec 6;9(1):293-305. doi: 10.18632/oncotarget.22968. eCollection 2018 Jan 2.

18.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

19.

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R.

J Clin Oncol. 2018 May 1;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394. Epub 2018 Jan 18.

PMID:
29346042
20.

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW.

Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.

21.

HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

di Martino S, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, Alessandrini G, Pass HI, Ciliberto G, Blandino G, De Maria R, Cioce M.

Oncogene. 2018 Mar;37(10):1369-1385. doi: 10.1038/s41388-017-0044-8. Epub 2018 Jan 9.

PMID:
29311642
22.

Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Ferdosi S, Rehder DS, Maranian P, Castle EP, Ho TH, Pass HI, Cramer DW, Anderson KS, Fu L, Cole DEC, Le T, Wu X, Borges CR.

J Proteome Res. 2018 Jan 5;17(1):543-558. doi: 10.1021/acs.jproteome.7b00672. Epub 2017 Nov 21.

PMID:
29129073
23.

Prognosis and "granularity": Building on staging foundations?

Pass HI.

J Thorac Cardiovasc Surg. 2018 Jan;155(1):354-355. doi: 10.1016/j.jtcvs.2017.10.032. Epub 2017 Oct 20. No abstract available.

PMID:
29100584
24.

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T.

Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2.

25.

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D.

Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.

26.

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.

Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, Guerrero-Preston R, Hoque MO.

Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.

PMID:
28855354
27.

Lepidic Predominant Pulmonary Lesions (LPL): CT-based Distinction From More Invasive Adenocarcinomas Using 3D Volumetric Density and First-order CT Texture Analysis.

Alpert JB, Rusinek H, Ko JP, Dane B, Pass HI, Crawford BK, Rapkiewicz A, Naidich DP.

Acad Radiol. 2017 Dec;24(12):1604-1611. doi: 10.1016/j.acra.2017.07.008. Epub 2017 Aug 24.

PMID:
28844845
28.

Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.

Szymiczek A, Carbone M, Pastorino S, Napolitano A, Tanji M, Minaai M, Pagano I, Mason JM, Pass HI, Bray MR, Mak TW, Yang H.

Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31.

29.

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Chen Z, Gaudino G, Pass HI, Carbone M, Yang H.

Transl Lung Cancer Res. 2017 Jun;6(3):259-269. doi: 10.21037/tlcr.2017.05.06. Review.

30.

Diagnosis and prognosis-review of biomarkers for mesothelioma.

Sun HH, Vaynblat A, Pass HI.

Ann Transl Med. 2017 Jun;5(11):244. doi: 10.21037/atm.2017.06.60. Review.

31.

Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules.

Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ.

Clin Proteomics. 2017 Jul 5;14:25. doi: 10.1186/s12014-017-9158-9. eCollection 2017.

32.

Quality Initiatives: Baby Steps in the Right Direction.

Pass HI.

Semin Thorac Cardiovasc Surg. 2017 Spring;29(1):102-103. doi: 10.1053/j.semtcvs.2017.03.005. Epub 2017 Mar 31.

PMID:
28683984
33.

Germline BAP1 mutations induce a Warburg effect.

Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, Xie G, Signorato V, Pastorino S, Morris P, Sakamoto G, Kuchay S, Gaudino G, Pass HI, Napolitano A, Pinton P, Jia W, Carbone M.

Cell Death Differ. 2017 Oct;24(10):1694-1704. doi: 10.1038/cdd.2017.95. Epub 2017 Jun 30.

34.

Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer.

Dai L, Li J, Tsay JJ, Yie TA, Munger JS, Pass H, Rom WN, Tan EM, Zhang JY.

Oncoimmunology. 2017 Mar 31;6(5):e1310359. doi: 10.1080/2162402X.2017.1310359. eCollection 2017.

35.

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M.

Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.

36.

Pleural IMRT after Lung-Sparing Cytoreduction for Mesothelioma: Mature Enough to Randomize.

Pass HI.

J Thorac Oncol. 2017 Jun;12(6):919-921. doi: 10.1016/j.jtho.2017.04.013. No abstract available.

37.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M.

J Clin Oncol. 2017 Sep 1;35(25):2960-2974. doi: 10.1200/JCO.2017.72.4401. Epub 2017 Apr 24. Review.

PMID:
28437162
38.

Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer.

Becker DJ, Levy BP, Gold HT, Sherman SE, Makarov DV, Schreiber D, Wisnivesky JP, Pass HI.

Am J Clin Oncol. 2018 Aug;41(8):820-825. doi: 10.1097/COC.0000000000000379.

PMID:
28301349
39.

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.

Szymiczek A, Pastorino S, Larson D, Tanji M, Pellegrini L, Xue J, Li S, Giorgi C, Pinton P, Takinishi Y, Pass HI, Furuya H, Gaudino G, Napolitano A, Carbone M, Yang H.

J Transl Med. 2017 Mar 15;15(1):58. doi: 10.1186/s12967-017-1158-z.

40.

Introduction: Great Institutions in Cardiothoracic Surgery, Second Edition.

Rosengart TK, Austin EH, Pass HI, Weisel RD.

Semin Thorac Cardiovasc Surg. 2016 Autumn;28(3):609-610. doi: 10.1053/S1043-0679(17)30038-2. No abstract available.

PMID:
28285664
41.

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.

Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H.

Oncotarget. 2017 Apr 4;8(14):22649-22661. doi: 10.18632/oncotarget.15152.

42.

Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.

Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, Gandara DR, Phinney BS, Fiehn O, Pass H, Miyamoto S.

Carcinogenesis. 2017 Jan 3. pii: bgw205. doi: 10.1093/carcin/bgw205. [Epub ahead of print] Review.

43.

Improving the Accuracy of Mesothelioma Diagnosis in China.

Guo Z, Carbone M, Zhang X, Su D, Sun W, Lou J, Gao Z, Shao D, Chen J, Zhang G, Hu J, Chen K, Wang F, Pass HI, Yu H, Napolitano A, Yang H, Mao W.

J Thorac Oncol. 2017 Apr;12(4):714-723. doi: 10.1016/j.jtho.2016.12.006. Epub 2016 Dec 19.

44.

Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China.

Mao W, Zhang X, Guo Z, Gao Z, Pass HI, Yang H, Carbone M.

JAMA Oncol. 2017 Apr 1;3(4):562-564. doi: 10.1001/jamaoncol.2016.5487. No abstract available.

45.

Long-Term Update of NRG Oncology RTOG 0319: A Phase 1 and 2 Trial to Evaluate 3-Dimensional Conformal Radiation Therapy Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma.

Rabinovitch R, Moughan J, Vicini F, Pass H, Wong J, Chafe S, Petersen I, Arthur DW, White J.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1054-1059. doi: 10.1016/j.ijrobp.2016.08.042. Epub 2016 Sep 3.

46.

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.

Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, Szymiczek A, Bononi A, Tanji M, Pagano I, Gaudino G, Napolitano A, Goparaju C, Pass HI, Yang H, Carbone M.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13432-13437. Epub 2016 Nov 9.

47.

Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.

Fahrmann JF, Grapov D, Phinney BS, Stroble C, DeFelice BC, Rom W, Gandara DR, Zhang Y, Fiehn O, Pass H, Miyamoto S.

Clin Proteomics. 2016 Oct 27;13:31. doi: 10.1186/s12014-016-9132-y. eCollection 2016.

48.

The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.

Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Nowak A, Rusch VW; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions.

J Thorac Oncol. 2016 Dec;11(12):2082-2088. doi: 10.1016/j.jtho.2016.09.123. Epub 2016 Sep 23. Review.

49.

Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity.

Larson D, Powers A, Ambrosi JP, Tanji M, Napolitano A, Flores EG, Baumann F, Pellegrini L, Jennings CJ, Buck BJ, McLaurin BT, Merkler D, Robinson C, Morris P, Dogan M, Dogan AU, Pass HI, Pastorino S, Carbone M, Yang H.

J Toxicol Environ Health B Crit Rev. 2016;19(5-6):213-230.

50.

The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advisory boards and participating institutions.

J Thorac Oncol. 2016 Dec;11(12):2100-2111. doi: 10.1016/j.jtho.2016.09.121. Epub 2016 Sep 26.

Supplemental Content

Support Center